Leadership Expansion Strengthens Operational and Commercial Strategy Following Pre-Seed Raise

Brisbane, Australia – December 11, 2026 – Following the successful close of its pre-seed funding round, Ketim Technologies has expanded its leadership team to accelerate clinical validation and commercial readiness.

Dr. Nathanael James Yates has been appointed Chief Operating Officer, bringing a decade of experience spanning neuroscience research, health policy, and commercial translation. With a Ph.D. in Neuroscience and research experience at The University of Western Australia and the Queensland Brain Institute, he has also shaped health technology strategy within Queensland Health and Nous Group, where he led research and publication of the Australian MedTech Report presented in Canberra. His background in translational pathways and commercialisation programs, including BridgeTech and Perth Biodesign, positions him to guide Ketim’s operational and regulatory strategy as the company advances toward market entry.

Joining the Board of Directors is Scott Fry, whose leadership experience includes scaling Vaxxas’ needle-free vaccine platform and contributing to Ellume’s launch of the first FDA-approved over-the-counter COVID-19 diagnostic test. His expertise in transitioning breakthrough science into globally deployed health technologies will support Ketim’s pathway from biomarker discovery to commercial diagnostics.

Andre Elcham also joins the Board, bringing extensive entrepreneurial and governance experience across high-growth ventures and public markets. His background in founding, scaling, and exiting companies, alongside capital markets leadership, will support Ketim’s global growth strategy.

“These appointments mark an important step in strengthening our leadership as we move from discovery into validation and commercial execution,” said Dr. Clarissa Yates, Founder and CEO. “Building the world’s first predictive blood-based diagnostic for postpartum depression requires operational discipline, translational expertise, and strategic oversight. This expanded team brings precisely that.”

The appointments reinforce Ketim’s commitment to advancing precision psychiatry through biomarker-driven diagnostics and preparing for clinical and global market milestones in the coming years.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au